Skip to content
Popular Searches
  • # Cancer
  • # FDA
  • # Alzheimer's
  • # Hoffmann-La Roche
  • # FDA Approval
  • # Diabetes
  • linkedin
  • facebook
  • instagram
  • twitter
  • youtube
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Research identified brain circuits for placebo effect pain relief

26 July 2024

Recurring COVID-19 vaccines produce antibodies that fight off other viruses and their variations.

22 May 2024

Pfizer released Phase 3 CREST trial results shows reduction of disease-related events in high-risk non-muscle invasive bladder cancer

29 April 2025

STELARA® (ustekinumab) for Pediatric Crohn’s Disease: Johnson & Johnson Files for FDA Approval

17 June 2025

Abbott Released New Clinical Trial Data Shows Long-Term Benefits of Voltâ„¢ PFA System

27 April 2025

Amgen Announces $900 Million Worth Expansion of Manufacturing Facility in the US

26 April 2025

Roche granted FDA breakthrough device designation for VENTANA TROP2, an AI-driven companion diagnostic for non-small cell lung cancer

29 April 2025

Roche Released Phase III CENTERSTONE Trial Data Showing Treatment With Xofluza Reduces Influenza Virus Transmission

25 April 2025

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for TrenibotulinumtoxinE (TrenibotE), Treating Glabellar Lines

24 April 2025

Blood test for Tuberculosis; researchers at the final phase of development

23 March 2024

Injection-free diabetes care; A new innovation in insulin-producing cells

8 November 2023

AbbVie’s RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis

30 April 2025

Myeloma

Johnson & Johnson’s DARZALEX FASPRO® Regimen Shows 95% 4-Year Progression-Free Survival in Newly Diagnosed Myeloma Patients
Clinical Trials Healthcare & Pharmaceuticals News

Johnson & Johnson’s DARZALEX FASPRO® Regimen Shows 95% 4-Year Progression-Free Survival in Newly Diagnosed Myeloma Patients

Athulya B S 3 June 2025

Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.

European Medicines Agency Panel Recommends Blenrep Combinations for Multiple Myeloma
Cancer Clinical Trials Regulatory

European Medicines Agency Panel Recommends Blenrep Combinations for Multiple Myeloma

Ajmal Aseem 24 May 2025

GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.

FDA Advisory Committee Recommends Johnson & Johnson’s DARZALEX FASPRO® for High-Risk Smoldering Multiple Myeloma
Cancer Healthcare & Pharmaceuticals News Regulatory

FDA Advisory Committee Recommends Johnson & Johnson’s DARZALEX FASPRO® for High-Risk Smoldering Multiple Myeloma

Athulya B S 22 May 2025

Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.

GSK’s Blenrep Combinations Approved in Japan for Relapsed or Refractory Multiple Myeloma
Healthcare & Pharmaceuticals News Regulatory Approval

GSK’s Blenrep Combinations Approved in Japan for Relapsed or Refractory Multiple Myeloma

Ajmal Aseem 20 May 2025

GSK’s Blenrep combinations have been approved in Japan for treating relapsed or refractory multiple myeloma, following strong Phase III trial results demonstrating improved survival outcomes.

CellCentric Secures $120 Million Investment to Develop Oral Myeloma Drug Inobrodib
Business Cancer Healthcare & Pharmaceuticals

CellCentric Secures $120 Million Investment to Develop Oral Myeloma Drug Inobrodib

Athulya B S 19 May 2025

CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Cytiva Hiring a Quality Control Technician in Cardiff, United Kingdom
  • PhD Position in Dialysis Therapy – University of Twente, Netherlands
  • Eli Lilly and Company Hiring a Analytical Technical Steward-Peptides in Hyderabad, India – June, 2025
  • ICON Hiring a Clinical Data Programming Lead in Chennai, India
  • PhD Position in Food Biotechnology – University of Reading, United Kingdom
SciRealityPress BiotechReality

A SciRealityPress Associate

DMCA.com Protection Status

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy